Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Trevena, Inc. is currently handling 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, indicating a multi-faceted prosecution approach. The busiest examiner, JAVANMARD, SAHAR, is responsible for 1 busiest examiner pending office action.
The use of 2 distinct examiners and 2 distinct art units suggests that the company patent portfolio covers a range of technical subjects within the Biotechnology & Pharmaceuticals sector. This diversification requires the legal team to adapt to different examination styles and art unit norms simultaneously. Since the busiest examiner manages 1 busiest examiner pending action, the workload is balanced across the 2 distinct examiners.
For practitioners, managing 2 pending office actions across 2 distinct art units requires a broad understanding of different USPTO guidelines. The outcome of the busiest examiner matter with JAVANMARD, SAHAR will be a key indicator of success, but it does not represent the entirety of the portfolio potential. Maintaining consistency across both examiners is essential for a cohesive intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAVANMARD, SAHAR | 1 | 64.8% | +34.1% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17879923 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | JAVANMARD, SAHAR | 147d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17879923 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | JAVANMARD, SAHAR | 147d overdue |
| 17639401 | METHODS OF TREATING EPILEPSY USING THE SAME | NESTOR, DONNA MICHELLE | 60d |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17879923 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | JAVANMARD, SAHAR | 1622 | §102§103Other | Final Rejection | 147d overdue | Pending | Aug 03, 2022 |
| 17639401 | METHODS OF TREATING EPILEPSY USING THE SAME | NESTOR, DONNA MICHELLE | 1627 | §103DPOther | Non-Final OA | 60d | Pending | Mar 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial